do-me/EUR-LEX huggingface dataset:
Case C-788/25 P: Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-278/23, Zentiva and Zentiva Pharma v Commission
Date: 2025-12-04
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600455EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/455


2.2.2026






Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-278/23, Zentiva and Zentiva Pharma v Commission


(Case C-788/25 P)

(C/2026/455)
Language of the case: English

Parties


Appellant: Biogen Netherlands BV (represented by: C. Schoonderbeek, A. Pothof, advocaten)

Other parties to the proceedings: Zentiva k.s., Zentiva Pharma GmbH, European Commission

Form of order sought

The appellant claims that the Court should:






—


set aside the judgement under appeal;










—


reject the application at first instance; and










—


order Zentiva k.s. and Zentiva Pharma GmbH to pay the costs.





Pleas in law and main arguments

In support of the appeal, the appellant rely on three grounds of appeal.
First ground of appeal: the General Court erred in the interpretation of Article 14(11) of Regulation (EC) No 726/2004 (1) by holding that this provision was violated by the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023.
Second ground of appeal: the General Court made a manifest error in the assessment of the facts in order to conclude on that basis that the judgment of the General Court of 5 May 2021, Pharmaceutical Works Polpharma v EMA (T-611/18) did not have any bearing on the lack of the grant of an authorisation for a new therapeutic indication for Tecfidera within the first eight years of the 10-year period of marketing protection for Tecfidera.
Third ground of appeal: the General Court misinterpreted Article 266 TFEU by holding that the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023 violated that provision.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/455/oj
ISSN 1977-091X (electronic edition)
Case C-279/24, Liechtensteinische Landesbank: Judgment of the Court (Fourth Chamber) of 4 December 2025 (request for a preliminary ruling from the Oberster Gerichtshof – Austria) – AY v Liechtensteinische Landesbank (Österreich) AG (Reference for a preliminary ruling – Judicial cooperation in civil matters – Regulation (EC) No 593/2008 – Article 3(1) and (2) – Choice of the applicable law – Article 6 – Scope – Contract concluded between a professional and a consumer residing in another Member State – Activity of the professional directed to the Member State in which the consumer has his or her habitual residence after the date of conclusion of the contract containing a choice-of-law clause)
Date: 2025-12-04
Institutions: Court of Justice
Subjects: bank, consumer protection, judicial cooperation in civil matters in the EU, private international law, residence, unfair terms of contract








C_202600609EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/609


9.2.2026






Judgment of the Court (Fourth Chamber) of 4 December 2025 (request for a preliminary ruling from the Oberster Gerichtshof – Austria) – AY v Liechtensteinische Landesbank (Österreich) AG


(Case C-279/24,
                (1)
Liechtensteinische Landesbank)

(Reference for a preliminary ruling - Judicial cooperation in civil matters - Regulation (EC) No 593/2008 - Article 3(1) and (2) - Choice of the applicable law - Article 6 - Scope - Contract concluded between a professional and a consumer residing in another Member State - Activity of the professional directed to the Member State in which the consumer has his or her habitual residence after the date of conclusion of the contract containing a choice-of-law clause)
(C/2026/609)
Language of the case: German

Referring court

Oberster Gerichtshof

Parties to the main proceedings


Applicant: AY

Defendant: Liechtensteinische Landesbank (Österreich) AG

Operative part of the judgment

Article 6(1) of Regulation (EC) No 593/2008 of the European Parliament and of the Council of 17 June 2008 on the law applicable to contractual obligations (Rome I)
must be interpreted as not applying to a contract concluded between a consumer and a bank where the conditions set out in that provision were not met on the date on which that contract was concluded, but are subsequently met.


(1)  OJ C, C/2024/4573.


ELI: http://data.europa.eu/eli/C/2026/609/oj
ISSN 1977-091X (electronic edition)
Case C-789/25 P: Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-351/23, Kern Pharma v Commission
Date: 2025-12-04
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600456EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/456


2.2.2026






Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-351/23, Kern Pharma v Commission


(Case C-789/25 P)

(C/2026/456)
Language of the case: English

Parties


Appellant: Biogen Netherlands BV (represented by: C. Schoonderbeek, A. Pothof, advocaten)

Other parties to the proceedings: Kern Pharma, SL, European Commission

Form of order sought

The appellant claims that the Court should:






—


set aside the judgement under appeal;










—


reject the application at first instance; and










—


order Kern Pharma, SL to pay the costs.





Pleas in law and main arguments

In support of the appeal, the appellant rely on three grounds of appeal.
First ground of appeal: the General Court erred in the interpretation of Article 14(11) of Regulation (EC) No 726/2004 (1) by holding that this provision was violated by the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023.
Second ground of appeal: the General Court made a manifest error in the assessment of the facts in order to conclude on that basis that the judgment of the General Court of 5 May 2021, Pharmaceutical Works Polpharma v EMA (T-611/18) did not have any bearing on the lack of the grant of an authorisation for a new therapeutic indication for Tecfidera within the first eight years of the 10-year period of marketing protection for Tecfidera.
Third ground of appeal: the General Court misinterpreted Article 266 TFEU by holding that the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023 violated that provision.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/456/oj
ISSN 1977-091X (electronic edition)
Case C-791/25 P: Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-299/23, Hexal AG v European Commission
Date: 2025-12-04
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600458EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/458


2.2.2026






Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-299/23, Hexal AG v European Commission



(Case C-791/25 P)

(C/2026/458)
Language of the case: German

Parties


Appellant: Biogen Netherlands BV (represented by: C. Schoonderbeek and A. Pothof, advocaten)

Other parties to the proceedings: Hexal AG, European Commission

Form of order sought

The appellant claims that the Court should:






—


set aside the judgment under appeal;










—


dismiss the action for annulment brought at first instance or refer the case back to the General Court;










—


order Hexal AG to pay the costs.





Grounds of appeal and main arguments

In support of its appeal, the appellant relies on three grounds of appeal, alleging:
First, that the General Court misinterpreted Article 14(11) of Regulation (EC) No 726/2004 (1) when it found that that provision had been infringed by Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023.
Second, that the General Court clearly misinterpreted the facts and, on the basis of that erroneous assessment, concluded that the judgment of the General Court of 5 May 2021 in Case T-611/18 (2) had no bearing on the refusal to authorise a new indication for Tecfidera within the first eight years of the ten-year marketing protection for Tecfidera.
Third, that the General Court misinterpreted Article 266 TFEU when it found that Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023 infringed that provision.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).

(2)  EU:T:2021:241


ELI: http://data.europa.eu/eli/C/2026/458/oj
ISSN 1977-091X (electronic edition)
Non-opposition to a notified concentration (Case M.12177 – CAPVEST / STADA GROUP)
Date: 2025-12-04
Institutions: Directorate-General for Competition, European Commission
Subjects: Arab world, Asia, Australia, Europe, economic concentration, merger control, pharmaceutical industry








C_202600190EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/190


6.1.2026






Non-opposition to a notified concentration
(Case M.12177 – CAPVEST / STADA GROUP)
(Text with EEA relevance)
(C/2026/190)

On 4 December 2025, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the ‘Competition policy’ website of the Commission (https://competition-cases.ec.europa.eu/search). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32025M12177. EUR-Lex is the online point of access to European Union law.






(1)  
            OJ L 24, 29.1.2004, p. 1.


ELI: http://data.europa.eu/eli/C/2026/190/oj
ISSN 1977-091X (electronic edition)
Prior notification of a concentration (Case M.12210 – PHOENIX / HAEMATO) – Candidate case for simplified procedure
Date: 2025-12-04
Institutions: Directorate-General for Competition, European Commission
Subjects: Austria, Germany, economic concentration, health care, logistics, merger control, pharmaceutical industry, pharmacy, retail trade, wholesale trade








C_202506531EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6531


4.12.2025






Prior notification of a concentration
(Case M.12210 – PHOENIX / HAEMATO)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2025/6531)


1.   
On 26 November 2025, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


PHOENIX Deutschland Holding GmbH (‘Phoenix’, Germany), controlled by PHOENIX Pharma SE (Germany),










—


HAEMATO PHARM GmbH (‘Haemato’, Germany), currently controlled by MPH Health Care AG (Germany).




Phoenix will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Haemato.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Phoenix is an integrated healthcare provider active in Germany and other European countries. It is mainly active in the wholesale distribution of pharmaceutical products, as well as in pharmacy retail, inventory management and logistics solutions, and other services for the pharmaceutical industry,










—


Haemato is a specialized wholesaler that distributes pharmaceutical products for HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology in Germany and Austria.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2), it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed concentration to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.12210 – PHOENIX / HAEMATO
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  
            OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  
            OJ C 160, 5.5.2023, p. 1.


ELI: http://data.europa.eu/eli/C/2025/6531/oj
ISSN 1977-091X (electronic edition)
Corrigendum to Council Decision (CFSP) 2025/2032 of 23 October 2025 amending Decision 2014/512/CFSP concerning restrictive measures in view of Russia’s actions destabilising the situation in Ukraine (OJ L, 2025/2032, 23.10.2025)
Date: 2025-12-04
Institutions: Council of the European Union
Subjects: EU restrictive measure, Russia, Russo-Ukrainian issue, Ukraine, economic sanctions, international sanctions, legal person, natural person, territorial dispute, territorial law, trade restriction








L_202590986EN.000101.fmx.xml












Official Journal of the European Union


EN
L series













2025/90986


4.12.2025






Corrigendum to Council Decision (CFSP) 2025/2032 of 23 October 2025 amending Decision 2014/512/CFSP concerning restrictive measures in view of Russia’s actions destabilising the situation in Ukraine
(
Official Journal of the European Union L, 2025/2032, 23 October 2025
)

On page 63, in the Annex, point (7)(a), in the column headed ‘Name of the legal person, entity or body’, final entry:







for:





                           ‘OJSC Commerzbank of Tajikistan’,












read:





                           ‘OJSC Commerce Bank of Tajikistan’.







ELI: http://data.europa.eu/eli/dec/2025/2032/corrigendum/2025-12-04/oj
ISSN 1977-0677 (electronic edition)
Council Decision of 4 December 2025 replacing an alternate member of the Management Board of the European Agency for Safety and Health at Work for Malta
Date: 2025-12-04
Institutions: Council of the European Union
Subjects: European Agency for Safety and Health at Work, Malta, appointment of members, decision-making body (EU)








C_202506584EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6584


10.12.2025







            COUNCIL DECISION
         
of 4 December 2025
         
replacing an alternate member of the Management Board of the European Agency for Safety and Health at Work for Malta
(C/2025/6584)


THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EU) 2019/126 of the European Parliament and of the Council of 16 January 2019 establishing the European Agency for Safety and Health at Work (EU-OSHA), and repealing Council Regulation (EC) No 2062/94 (1), and in particular Article 4 thereof,

Whereas:







(1)


By Decision of 28 March 2023 (2), the Council appointed members and alternate members of the Management Board of the European Agency for Safety and Health at Work for the period from 1 April 2023 to 31 March 2027.












(2)


A seat as alternate member in the government representatives category has fallen vacant as a result of the resignation of Mr Silvio FARRUGIA.












(3)


The Government of Malta has designated a candidate for the vacant seat,





HAS ADOPTED THIS DECISION:



Article 1
Ms Josianne CUTAJAR is appointed alternate member of the Management Board of the European Agency for Safety and Health at Work in place of Mr Silvio FARRUGIA for the remainder of the current term of office, ending on 31 March 2027.


Article 2
This Decision shall enter into force on the date of its adoption.




Done at Brussels, 4 December 2025.


For the Council


The President

T. DANIELSEN
            





(1)  
            OJ L 30, 31.1.2019, p. 58.

(2)  Council Decision of 28 March 2023 appointing members and alternate members of the Management Board of the European Agency for Safety and Health at Work (EU-OSHA) (OJ C 116, 31.3.2023, p. 19).


ELI: http://data.europa.eu/eli/C/2025/6584/oj
ISSN 1977-091X (electronic edition)
Case C-786/25 P: Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-257/23, Neuraxpharm Pharmaceuticals v Commission
Date: 2025-12-04
Institutions: Court of Justice
Subjects: disease of the nervous system, drug surveillance, market approval, medicinal product








C_202600453EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2026/453


2.2.2026






Appeal brought on 4 December 2025 by Biogen Netherlands BV against the judgment of the General Court (Fourth Chamber) delivered on 24 September 2025 in Case T-257/23, Neuraxpharm Pharmaceuticals v Commission


(Case C-786/25 P)

(C/2026/453)
Language of the case: English

Parties


Appellant: Biogen Netherlands BV (represented by: C. Schoonderbeek, A. Pothof, advocaten)

Other parties to the proceedings: Neuraxpharm Pharmaceuticals SL, European Commission

Form of order sought

The appellant claims that the Court should:






—


set aside the judgment under the appeal;










—


reject the application at first instance; and










—


order Neuraxpharm Pharmaceuticals SL to pay the costs.





Pleas in law and main arguments

In support of the appeal, the appellant rely on three grounds of appeal.
First ground of appeal: the General Court erred in the interpretation of Article 14(11) of Regulation (EC) No 726/2004 (1) by holding that this provision was violated by the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023.
Second ground of appeal: the General Court made a manifest error in the assessment of the facts in order to conclude on that basis that the judgment of the General Court of 5 May 2021, Pharmaceutical Works Polpharma v EMA (T-611/18) did not have any bearing on the lack of the grant of an authorisation for a new therapeutic indication for Tecfidera within the first eight years of the 10-year period of marketing protection for Tecfidera.
Third ground of appeal: the General Court misinterpreted Article 266 TFEU by holding that the Commission Implementing Decision C(2023) 3067 (final) of 2 May 2023 violated that provision.


(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).


ELI: http://data.europa.eu/eli/C/2026/453/oj
ISSN 1977-091X (electronic edition)
Non-opposition to a notified concentration (Case M.12096 – BPCE / NOVO BANCO)
Date: 2025-12-04
Institutions: Directorate-General for Competition, European Commission
Subjects: France, Portugal, banking, economic concentration, financial services, insurance, merger control








C_202506708EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6708


16.12.2025






Non-opposition to a notified concentration
(Case M.12096 – BPCE / NOVO BANCO)
(Text with EEA relevance)
(C/2025/6708)

On 4 December 2025, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the ‘Competition policy’ website of the Commission (https://competition-cases.ec.europa.eu/search). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32025M12096. EUR-Lex is the online point of access to European Union law.






(1)  
            OJ L 24, 29.1.2004, p. 1.


ELI: http://data.europa.eu/eli/C/2025/6708/oj
ISSN 1977-091X (electronic edition)
Non-opposition to a notified concentration (Case M.12232 – BRIDGEPOINT / BAIN CAPITAL CREDIT / NATIVE INSTRUMENTS GROUP)
Date: 2025-12-04
Institutions: Directorate-General for Competition, European Commission
Subjects: computer equipment, credit institution, economic concentration, investment company, merger control, software








C_202506769EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/6769


22.12.2025






Non-opposition to a notified concentration
(Case M.12232 – BRIDGEPOINT / BAIN CAPITAL CREDIT / NATIVE INSTRUMENTS GROUP)
(Text with EEA relevance)
(C/2025/6769)

On 4 December 2025, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the ‘Competition policy’ website of the Commission (https://competition-cases.ec.europa.eu/search). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32025M12232. EUR-Lex is the online point of access to European Union law.






(1)  
            OJ L 24, 29.1.2004, p. 1.


ELI: http://data.europa.eu/eli/C/2025/6769/oj
ISSN 1977-091X (electronic edition)